Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

Blood (2025) 146 (Supplement 1): 399.

https://doi.org/10.1182/blood-2025-399

Published: 2025

Journal Articles

DLBCL tumor microenvironment archetype and CD4+ T cell conversion to cytotoxic cells are required for response to glofitamab

Thiago Maass Steiner, Bao Le, Sean Harrop, Faiza ZuairiaTabassum, Lucas Tobar, Ruiqing Zhu, Sean Macdonald, LeiShong Lau, Vivien Sutton, Joseph Trapani, Niko Thio, Adrian Minson, Michael Dickinson, Paul Neeson

Blood (2025) 146 (Supplement 1): 557.

https://doi.org/10.1182/blood-2025-557

Published: 2025

Journal Articles

Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma

Malgorzata Nowicka, Wilfred Leung, Carmelo Carlo-Stella, Michael Dickinson, Martin Hutchings, Estefania Mulvihill, Linda Lundberg, Habib Hamidi, Alessia Bottos

Blood (2025) 146 (Supplement 1): 5316.

https://doi.org/10.1182/blood-2025-5316

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

Catelyn Cashion, Jian Li, Sergio Farina, Shafqat Inam, Anthony Jeffrey, Ross MacDonald, Thomas Buss, Vinay Vanguru, Stephen Boyle, David Bishop, Christina Brown, Allison Barraclough, Constantine Tam, Andrea Henden, Michael Dickinson, Emily Blyth, Mark Dowling

Blood (2025) 146 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2025-1936

Published: 2025

Journal Articles

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Jian Li, Mark Dowling, Anthony Jeffrey, Sergio Farina, Stephen Boyle, Ross MacDonald, Shafqat Inam, Chun Kei Kris Ma, Vinay Vanguru, Nilu Perera, Hamish Scott, Michael Dickinson, John Seymour, Andrea Henden, Emily Blyth, Phoebe Joy Ho, Constantine Tam, Mary Ann Anderson, Philip Thompson

Blood (2025) 146 (Supplement 1): 2779.

https://doi.org/10.1182/blood-2025-2779

Published: 2025

Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 811.

https://doi.org/10.1182/blood-2025-811

Published: 2025

Journal Articles

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Krish Patel, Jennifer Crombie, Tycel Phillips, Michael Dickinson, Toby Eyre, Chan Cheah, Stephen Schuster, Nirav Shah, Georg Lenz, Laurie Sehn, Donald Tsai, Erica Johnston, Sonya Chapman, Hongmei Han, Minna Balbas, Ching Ching Leow, Gilles Salles

Blood (2025) 146 (Supplement 1): 5524.

https://doi.org/10.1182/blood-2025-5524

Published: 2025

Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Chad M. Williams, Joshua Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2025) 145 (20): 2303–2311.

https://doi.org/10.1182/blood.2024027347

Published: 2025

Includes: Supplemental data

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma

Imogen Caldwell, Yan Zhuang Yap, Mark R Dowling, Javad Saghebi, Aaron Jun Ning Wong, Roxane Legaie, Rainier Arnolda, Clarissa Wilson, Danielle Ignacio, Nicole O'Leary, Stephanie Yaung, Bowdoin Su, Corinna Woestmann, Michael Dickinson, Ella Thompson, Piers Blombery

Blood (2023) 142 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2023-182999

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood (2023) 142 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2023-174081

Published: 2023

Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 894.

https://doi.org/10.1182/blood-2023-174510

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 9461–9463.

https://doi.org/10.1182/blood-2022-157011

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

DLBCL tumor microenvironment archetype and CD4+ T cell conversion to cytotoxic cells are required for response to glofitamab

Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only